Investor Service Announcement no. 3/2011



To: NASDAQ OMX Copenhagen
Hørsholm, Denmark, May 23, 2011



LifeCycle Pharma to Present at Two Upcoming Investor Conferences



-- UBS Global Specialty Pharmaceuticals Conference, May 24, London
-- ThinkEquity 2nd Annual Healthcare Conference, May 25, New York City

LifeCycle Pharma A/S (OMX: LCP) today announced presentations at two upcoming
investor conferences. John D. Weinberg, M.D., Senior Vice president of
Commercial Operations and Investor Relations will present at the UBS Global
Specialty Pharmaceuticals Conference at 4 p.m. BST on May 24 in London, UK. In
addition, William J. Polvino, M.D., President and Chief Executive Officer, will
present at the ThinkEquity 2nd Annual Healthcare Conference: A Mid Year Check
Up at 10:30 a.m. EST, May 25, 2011, at the Princeton Club in New York City.
Drs. Polvino and Weinberg will provide an overview of the company and its lead
Phase 3 candidate to prevent organ transplant rejection, LCP-Tacro(TM).



For more information, please contact:



LifeCycle Pharma A/S Johnny Stilou
John D. Weinberg, M.D. CFO
SVP, Commercial Operations and Investor Relations Phone: + 45 2055 3817
Phone: +1 732 321 3208 Email: [email protected]
Email: [email protected]



About LifeCycle Pharma A/S (LCP)

Based in Hørsholm, Denmark, with an office in New Jersey, LCP is a specialty
pharmaceutical company. Clinical development is the core of LCP's efforts to
develop a product portfolio which includes the Company's lead product
candidate, LCP‐Tacro™, for immunosuppression, specifically organ
transplantation, and products to combat certain cardiovascular diseases. LCP
adapts new technologies on a fast commercial timetable. LCP's unique, patented
delivery technology, MeltDose®, can improve absorption and bioavailability ‐ at
low‐scale up costs ‐ not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a lipid lowering product,
Fenoglide®, currently on the U.S. market and a diversified near and medium term
pipeline with three clinical stage product candidates and a number of projects
in preclinical development. LCP is listed on the NASDAQ OMX Copenhagen under
the trading symbol OMX: LCP.

For further information, please visit www.lcpharma.com

230511 LifeCycle Pharma Present at Two Upcoming Investor Conferences.pdf